NASDAQ
MDWD
Last Price
US $14.25
Valuation
Financial
Performance
Financial risk - Cash flow debt coverage.
MediWound Ltd. cash flow to debt ratio of -178.24% indicates that the company cannot generate enough cash to cover its debt over time. This level indicates weak financial health.
Financial risk - Healthy cash flow growth.
MediWound Ltd.'s free cash flow has decreased 0.69% from $-19.90M last year to $-20.04M, signaling decreasing performance
Financial stability - Healthy debt to equity ratio.
MediWound Ltd.'s debt to equity ratio is 0.20, which means that the company's assets are healthy financed, signaling financial stability. READ MORE: A ratio under 0.60 means the company finances its assets with own equity, signaling financial stability and good management.
Financial stability - Healthy debt to equity ratio development.
MediWound Ltd.'s debt has decreased relative to shareholder equity from 0.22 last year to 0.20 today, signaling strengthened financials
Financial risk - Net debt/EBITDA.
MediWound Ltd. has negative EBITDA, making leverage ratio unreliable
Financial stability - ICR.
MediWound Ltd. earns at least as much interest as it pays. Interest obligations are fully covered.
Financial risk - Profit margin growth.
MediWound Ltd.'s profit margin has decreased (20.63%) in the last year from -149.46% to -180.30%, signaling decreasing performance
Financial stability - Short term assets vs short term liabilities.
MediWound Ltd.'s short-term assets of $59.96M exceed its short-term liabilities of $25.71M
Decreasing performance - ROA.
MediWound Ltd.'s return on assets of 0.00% is lower than the 5.00% threshold, indicating inefficient asset utilization
Decreasing performance - Absolute return on equity.
MediWound Ltd.'s return on equity of -67.22%, is lower than 15.00%, indicating bad performance
Decreasing performance - Earnings quality.
MediWound Ltd.'s operating cash flow is lower than its net income, indicating that earnings may not be fully backed by cash generation
Decreasing performance - Earnings stability.
MediWound Ltd. had positive net income in only 0.00 out of 5 years, indicating unstable earnings
Decreasing performance - Free cash flow.
MediWound Ltd. has negative free cash flow, indicating the company is burning cash rather than generating it
Decreasing performance - FCF yield.
MediWound Ltd. has negative free cash flow, indicating cash burn
Increasing performance - Healthy earnings growth.
MediWound Ltd.'s yearly earnings has increased -20.99% since last year from $-30.22M to $-23.88M, signaling increasing performance
Decreasing performance - Healthy revenue growth.
MediWound Ltd.'s yearly revenue has decreased -16.14% since last year from $20.22M to $16.96M, signaling decreasing performance
Decreasing performance - ROIC.
ROIC -47.30% (Source: FMP key-metrics). Below the 5% partial-credit threshold. Score: 0 of 2. The 5% and 10% cutoffs anchor to typical US weighted-average cost of capital. Below 5% indicates the company is not generating returns above its likely cost of capital under this definition of invested capital. Invested capital here includes equity, non-current liabilities (pension obligations, deferred taxes, lease obligations), and short-term debt. Cash is not subtracted. Companies with substantial float, lease portfolios, or cash holdings will score lower under this definition than under narrower operating-capital definitions. See methodology.
Decreasing performance - 3-year revenue CAGR.
MediWound Ltd.'s 3-year revenue CAGR of -13.82% is negative, indicating declining revenue over the past 3 years
Increasing performance - Revenue consistency.
MediWound Ltd. had revenue growth in 3.00 out of 5 years, indicating consistent revenue performance
Decreasing performance - ROE consistency.
MediWound Ltd. had positive ROE in only 0.00 out of 5 years, indicating inconsistent returns on equity
Overvalued - DCF valuation.
MediWound Ltd. has insufficient data to evaluate this check.
Overvalued - Earnings yield.
MediWound Ltd. has negative trailing-twelve-month earnings; this ratio is not meaningful and the check fails
Overvalued - EBITDA valuation.
MediWound Ltd. is overvalued relative to its fair value price of 0.00 based on EBITDA multiple model
Overvalued - EV/EBITDA.
MediWound Ltd. has negative or missing EBITDA, making EV/EBITDA ratio unreliable
Overvalued - PEG ratio value.
MediWound Ltd. has negative trailing-twelve-month earnings; this ratio is not meaningful and the check fails
Undervalued - P/B ratio.
MediWound Ltd. has a price-to-book ratio of 4.43x, which is below the 5.00x threshold, indicating reasonable valuation relative to its book value
Overvalued - P/S ratio.
MediWound Ltd. has a price-to-sales ratio of 12.67x, which exceeds the 8.00x threshold, indicating the stock may be overvalued relative to its revenue
Profit margin
Current Ratio
Capital Returns
-67.22%
Return on equity
ROIC: -47.30%
Valuation History
-6.3X
Price to Earnings
EV/EBITDA: -8X
Cash flow
Profit margin
-19.29%
(FY vs FY)
Cash flow Y/Y
-17.16%
(FY vs FY)
Fair Value
Market $14.25
—
Default assumptions
Base valuations use default assumptions. Customize in the Valuator.